For the Inventor, By the Inventor

Enter assignee name

Blacksburg, VA, United States of America

Revivicor, Inc.

USPTO Granted Patents = 16

% Expired Patents = 25.0

CIPO Patents = 5

EPO Patents = 7

Trademarks = 3

Forward Citations = 133

Loading Chart...

Loading Chart...

8 inventors (with patents filed for the assignee):

David Ayares (14 out of 14 patents)

Kevin Wells (4 out of 4 patents)

Paul Rohricht (3 out of 3 patents)

4. Carol J Phelps (2 out of 4 patents)

5. Michael Mendicino (1 out of 1 patent)

6. Amy S Dandro (1 out of 1 patent)

7. Maria Kokkinaki (1 out of 1 patent)

8. Kasinath V Kuravi (1 out of 1 patent)

9. Carol Phelps (1 out of 1 patent)

10. Angelika Elisabeth Schnieke (1 patent)

11. David Lee Ayares (0 patent)

12. Alexander Jarvis Kind (0 patent)

13. Alan Colman (0 patent)

14. Yifan Dai (0 patent)

16 patents: Sort by Forward Citations

1. 12714077 - Multi-transgenic pig for Xenotransplantation (2026-08-25),

2. 12648548 - MULTITRANSGENIC PIGS COMPRISING TEN GENETIC MODIFICATIONS FOR XENOTRANSPLANTATION (2026-06-09),

3. 12569592 - GENETICALLY MODIFIED PIGS FOR XENOTRANSPLANTATION OF VASCULARIZED XENOGRAFTS AND DERIVATIVES THEREOF (2026-03-10),

4. 11179496 - Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof (2021-11-23),

5. 11172658 - Porcine animals lacking expression of functional alpha 1, 3 galactosyltransferase (2021-11-16),

6. 11085054 - Ungulates with genetically modified immune systems (2021-08-10),

7. 10912863 - Tissue products derived from animals lacking any expression of functional alpha 1, 3 galactosyltransferase (2021-02-09),

8. 10793873 - Use of interfering RNA in the production of transgenic animals (2020-10-06),

9. 10383317 - Multi-transgenic pigs for diabetes treatment (2019-08-20),

10. 10300112 - Transgenic ungulates expressing CTLA4-IG and uses thereof (2019-05-28),

11. 10149461 - Immunocompromised ungulates (2018-12-11),

12. 10130737 - Tissue products derived from animals lacking any expression of functional alpha 1, 3 galactosyltransferase (2018-11-20),

13. 9585374 - Ungulates with genetically modified immune systems (2017-03-07),

14. 9339519 - Multi-transgenic pigs for diabetes treatment (2016-05-17),

15. 8106251 - Tissue products derived from porcine animals lacking any expression of functional alpha 1,3 galactosyltransferase (2012-01-31),

Revivicor, Inc. is a biotechnology company based in Blacksburg, Virginia, specializing in regenerative medicine and organ transplantation. The organization focuses on developing innovative solutions to address the challenges of organ shortages and improve transplant outcomes. By leveraging advanced genetic engineering techniques, Revivicor aims to create viable organ alternatives and enhance the field of xenotransplantation, ultimately contributing to better healthcare solutions and patient quality of life.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Oct 6 2026

Revivicor, Inc.

16 Patents

#10 in Blacksburg, VA

#332 in Virginia

#19,907 in US

#37,788 in the World

Blacksburg, VA, United States of America

Revivicor, Inc.

Forward Citations = 133

8 inventors:

David Ayares (14 out of 14 patents)

Kevin Wells (4 out of 4 patents)

Paul Rohricht (3 out of 3 patents)

4. Carol J Phelps (2 out of 4 patents)

5. Michael Mendicino (1 out of 1 patent)

Please report any incorrect information to [email protected]

Loading…